Compare Arqit Quantum Inc (ARQQ) vs Summit Therapeutics Inc (SMMT) Price & Performance

ARQQ trades at $23.72, up 4.91% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows explosive revenue growth but deep losses, with a P/S ratio of 352.9 reflecting high growth expectations. Recent news highlights a proof-of-concept with nLighten and strong H1 2026 revenue growth of 829% year-over-year, signaling commercial traction in quantum-safe encryption.

Outlook hinges on scaling revenue to offset high costs, with analyst sentiment split evenly between Buy and Hold. Key risks include sustained cash burn and competitive pressure, but government and telecom deals offer upside if execution improves.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.